CR Pharma
ActiveCR Pharma has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €813k and a net result of €190k. Equity is growing by ~168.5% per year across the filed fiscal years. Its solvency ranks better than 47% of 2273 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2025
71
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability80▲+31
Solvency63▲+4
Growth78=
Track record94
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €55k at 30 days acceptable
Liquidity short (current ratio 0.79 against 1.11 in 2024; short-term debt: 14.2% and cash: 10.5% of total assets), and 62.3% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 82
Relative position
BE, all sectors
reference
Sector 82
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
37.7%
Return on assets
8.8%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-05-2026, 70 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
70 d early
2024
16 d early
2023
37 d early
2022
40 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
22-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€813k▲ 7.9%
2024 · €753k
2022: €49k
2023: €101k
2024: €753k
2022 → 2025
Total assets
€2.16M▼ 2.5%
2024 · €2.21M
2022: €72k
2023: €125k
2024: €2.21M
2022 → 2025
Net result
€190k▲ 261%
2024 · €53k
2022: €46k
2023: €53k
2024: €53k
2022 → 2025
Working capital
€-65k
2024 · €30k
2022: €48k
2023: €101k
2024: €30k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€49k-€101k▲ 105%€753k▲ 643%€813k▲ 7.9%
Operating result€59k-€67k▲ 13.2%€88k▲ 32.1%€285k▲ 224%
Net result€46k-€53k▲ 14.5%€53k▼ 0.4%€190k▲ 261%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has risen three years in a row; 2025 is 224% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.16M
Fixed assets
€1.92M▲ 0.8%
Current assets
€241k▼ 22.7%
Equity and liabilities €2.16M
Equity
€813k▲ 7.9%
Debt
€1.34M▼ 7.9%
The debt ratio falls from 66.0% to 62.3%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€286k▲
2024 · €89k
Cash flow
€190k▲
2024 · €53k
Solvency
37.7%▲
2024 · 34.0%
Current ratio
0.79▼
2024 · 1.11
Quick ratio
0.79▼
2024 · 1.11
Debt / equity
1.65▼
2024 · 1.94
ROE
23.4%▲
2024 · 7.0%
ROA
8.8%▲
2024 · 2.4%
Interest coverage
7.12▲
2024 · 3.29
Debt
€1.34M▼
2024 · €1.46M
Debt ≤ 1 year
€306k▲
2024 · €281k
Debt > 1 year
€1.04M▼
2024 · €1.18M
Income taxes
€58k▲
2024 · €14k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€2.21M€2.16M▼
Fixed assets21/28€1.90M€1.92M▲
Tangible fixed assets22/27€2k€1k▼
Furniture and vehicles24€2k€1k▼
Financial fixed assets28€1.90M€1.92M▲
Current assets29/58€312k€241k▼
Amounts receivable within one year40/41€16k€15k▼
Trade receivables40€16k€15k▼
Other amounts receivable41€0-
Current investments50/53€250k€0▼
Cash at bank and in hand54/58€45k€226k▲
Deferred charges and accrued income490/1€1k€206▼
Equity and liabilities
Total equity and liabilities10/49€2.21M€2.16M▼
Equity10/15€753k€813k▲
Contributions10/11€604k€604k=
Reserves13€149k€209k▲
Distributable reserves133€149k€209k▲
Profit (loss) carried forward14€0€0=
Amounts payable17/49€1.46M€1.34M▼
Amounts payable after more than one year17€1.18M€1.04M▼
Financial debts170/4€1.18M€1.04M▼
Amounts payable within one year42/48€281k€306k▲
Current portion of amounts payable after more than one year42€140k€140k=
Trade debts44€1k€966▼
Suppliers440/4€1k€966▼
Taxes, remuneration and social security45€22k€15k▼
Taxes450/3€21k€14k▼
Remuneration and social security454/9€1k€1k=
Other amounts payable47/48€118k€150k▲
Accrued charges and deferred income492/3€590€300▼
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€591€603▲
Other operating charges640/8€501€915▲
Non-recurring operating charges66A€53€150▲
Gross operating margin9900€89k€287k▲
Operating profit (loss)9901€88k€285k▲
Financial income75/76B€6k€3k▼
Recurring financial income75€6k€3k▼
Financial charges65/66B€27k€40k▲
Recurring financial charges65€27k€40k▲
Profit (loss) for the period before taxes9903€67k€248k▲
Income taxes67/77€14k€58k▲
Profit (loss) for the period9904€53k€190k▲
Profit (loss) for the period to be appropriated9905€53k€190k▲
Appropriation of the result
Profit (loss) to be appropriated9906€53k€190k▲
Transfer to equity691/2€52k€60k▲
To other reserves6921€52k€60k▲
Profit to be distributed694/7€859€130k▲
Return on contributions (dividend)694€859€130k▲
Social balance
Average headcount (FTE)90870.00.0=
The notes to these accounts (17 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
22-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Highest result since 2022net €190k ▲261%
Operating result €285k, net result €190k, both a record.
15-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Equity above €500kEq €753k ▲643%
3 profitable years in a row build equity to €753k.
24-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Equity above €100kEq €101k ▲105%
2 profitable years in a row build equity to €101k.
21-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Harelbeke · 1 establishment unit since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Overleiestraat 1178530 HarelbekeGround area
1,101 m²
Building footprint
476 m²
Volume, LiDAR
2,892 m³
2 parcels, Flanders · tallest building 11.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
CR Pharma
since 20222.326.254.196
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 34023B0694/00W007 | Flanders | 726 m² | 1 · 125 m² | 11.8 m · 3 fl. |
| 34323D0072/00R005 | Flanders | 376 m² | 1 · 351 m² | 11.9 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2023 · 1 entry · 75 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2023 | 1 | 0 EUR | 75 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Similar companies · same sector, comparable size
Cloudworks
BE 0772.679.036
Kraainem · Eq €814k
PETER VELDEMAN
BE 0808.597.245
Sint-Martens-Latem · Eq €814k
VELT vzw, VERENIGING VOOR ECOLOGISCH LEVEN EN TUINIEREN
BE 0413.977.093
Antwerpen · Eq €814k
All Experts
BE 0646.729.484
Wingene · Eq €815k
J2V
BE 0818.107.205
Wetteren · Eq €816k
Of 24,503 companies in sector 82990 we hold annual accounts for 9,402. 4,957 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded10-01-2022
Fiscal year end31-12
Activities, NACEBEL
82990Other business support services
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Data from official sources, last processed on 22-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:Charlotte.raes@outlook.com